Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: Results from the PRECOVID study in Spain

Poblador-Plou, B. ; Carmona-Pírez, J. ; Ioakeim-Skoufa, I. ; Poncel-Falcó, A. ; Bliek-Bueno, K. ; Cano-Del Pozo, M. ; Gimeno-Feliú, L.A. (Universidad de Zaragoza) ; González-Rubio, F. ; Aza-Pascual-salcedo, M. ; Bandrés-Liso, A.C. ; Díez-Manglano, J. (Universidad de Zaragoza) ; Marta-Moreno, J. (Universidad de Zaragoza) ; Mucherino, S. ; Gimeno-Miguel, A. ; Prados-Torres, A. ; Clerencia-Sierra, M. ; Coscollar-Santaliestra, C. ; de Alba, I.G.F. ; Moreno-Juste, A. ; Pico-Soler, V. ; Ara-Bardají, P. ; EpiChron, Group

Resumen: We aimed to analyze baseline socio-demographic and clinical factors associated with an increased likelihood of mortality in men and women with coronavirus disease (COVID-19). We conducted a retrospective cohort study (PRECOVID Study) on all 4412 individuals with laboratory-confirmed COVID-19 in Aragon, Spain, and followed them for at least 30 days from cohort entry. We described the socio-demographic and clinical characteristics of all patients of the cohort. Age-adjusted logistic regressions models were performed to analyze the likelihood of mortality based on demographic and clinical variables. All analyses were stratified by sex. Old age, specific diseases such as diabetes, acute myocardial infarction, or congestive heart failure, and dispensation of drugs like vasodilators, antipsychotics, and potassium-sparing agents were associated with an increased likelihood of mortality. Our findings suggest that specific comorbidities, mainly of cardiovascular nature, and medications at the time of infection could explain around one quarter of the mortality in COVID-19 disease, and that women and men probably share similar but not identical risk factors. Nonetheless, the great part of mortality seems to be explained by other patient-and/or health-system-related factors. More research is needed in this field to provide the necessary evidence for the development of early identification strategies for patients at higher risk of adverse outcomes.

Idioma: Inglés

DOI: 10.3390/ijerph17145171

Año: 2020

Publicado en: International journal of environmental research and public health 17, 14 (2020), 5171 1-14
ISSN: 1661-7827

Factor impacto JCR: 3.39 (2020)

Categ. JCR: PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH rank: 41 / 175 = 0.234 (2020) - Q1 - T1
Categ. JCR: PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH rank: 68 / 202 = 0.337 (2020) - Q2 - T2
Categ. JCR: ENVIRONMENTAL SCIENCES rank: 118 / 273 = 0.432 (2020) - Q2 - T2

Factor impacto SCIMAGO: 0.747 - Health, Toxicology and Mutagenesis (Q2) - Public Health, Environmental and Occupational Health (Q2) - Pollution (Q2)

Financiación: info:eu-repo/grantAgreement/ES/DGA-FEDER/B01-20R
Financiación: info:eu-repo/grantAgreement/ES/DGA/PI20-226

Tipo y forma: Artículo (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)